Username

Password

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Kenneth Davis

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Disorders

Activities & Behaviors

Schizophrenic Psychology

Concepts & Ideas

Anatomy

Brain

Chemicals & Drugs

Living Beings

Rats

Procedures

Clinical Trials as Topic

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Katsel Pavel; Davis Kenneth L; Li Celeste; Tan Weilun; Greenstein Elizabeth; Kleiner Hoffman Lisa B; Haroutunian Vahram
Abnormal indices of cell cycle activity in schizophrenia and their potential association with oligodendrocytes.
Carpenter David M; Tang Cheuk Y; Friedman Joseph I; Hof Patrick R; Stewart Daniel G; Buchsbaum Monte S; Harvey Philip D; Gorman Jack G; Davis Kenneth L
Temporal characteristics of tract-specific anisotropy abnormalities in schizophrenia.
Friedman Joseph I; Tang Cheuk; Carpenter David; Buchsbaum Monte; Schmeidler James; Flanagan Lauren; Golembo Shana; Kanellopoulou Isabella; Ng Johnny; Hof Patrick R; Harvey Philip D; Tsopelas Nicholas D; Stewart Daniel; Davis Kenneth L
Diffusion tensor imaging findings in first-episode and chronic schizophrenia patients.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Kenneth Davis (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2008: Katsel Pavel; Davis Kenneth L; Li Celeste; Tan Weilun; Greenstein Elizabeth; Kleiner Hoffman Lisa B; Haroutunian Vahram
Abnormal indices of cell cycle activity in schizophrenia and their potential association with oligodendrocytes.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2008;33(12):2993-3009.
2008: Carpenter David M; Tang Cheuk Y; Friedman Joseph I; Hof Patrick R; Stewart Daniel G; Buchsbaum Monte S; Harvey Philip D; Gorman Jack G; Davis Kenneth L
Temporal characteristics of tract-specific anisotropy abnormalities in schizophrenia.
Neuroreport 2008;19(14):1369-72.
2008: Friedman Joseph I; Tang Cheuk; Carpenter David; Buchsbaum Monte; Schmeidler James; Flanagan Lauren; Golembo Shana; Kanellopoulou Isabella; Ng Johnny; Hof Patrick R; Harvey Philip D; Tsopelas Nicholas D; Stewart Daniel; Davis Kenneth L
Diffusion tensor imaging findings in first-episode and chronic schizophrenia patients.
The American journal of psychiatry 2008;165(8):1024-32.
2008: Stewart Daniel G; Davis Kenneth L
The lobotomist.
The American journal of psychiatry 2008;165(4):457-8.
2008: Friedman Joseph I; Davis Kenneth L; Chang Linda; Ernst Thomas; Tsopelas Nicholas D; Zhong Kai
Relationships between white matter metabolite abnormalities, cognitive and social functioning in elderly schizophrenic subjects.
Schizophrenia research 2008;100(1-3):356-8.
2008: Friedman J I; Vrijenhoek T; Markx S; Janssen I M; van der Vliet W A; Faas B H W; Knoers N V; Cahn W; Kahn R S; Edelmann L; Davis K L; Silverman J M; Brunner H G; van Kessel A Geurts; Wijmenga C; Ophoff R A; Veltman J A
CNTNAP2 gene dosage variation is associated with schizophrenia and epilepsy.
Molecular psychiatry 2008;13(3):261-6.
2008: Buxbaum J D; Georgieva L; Young J J; Plescia C; Kajiwara Y; Jiang Y; Moskvina V; Norton N; Peirce T; Williams H; Craddock N J; Carroll L; Corfas G; Davis K L; Owen M J; Harroch S; Sakurai T; O'Donovan M C
Molecular dissection of NRG1-ERBB4 signaling implicates PTPRZ1 as a potential schizophrenia susceptibility gene.
Molecular psychiatry 2008;13(2):162-72.
2008: Byne William; Dracheva Stella; Chin Benjamin; Schmeidler James M; Davis Kenneth L; Haroutunian Vahram
Schizophrenia and sex associated differences in the expression of neuronal and oligodendrocyte-specific genes in individual thalamic nuclei.
Schizophrenia research 2008;98(1-3):118-28.
2007: Chang Linda; Friedman Joseph; Ernst Thomas; Zhong Kai; Tsopelas Nicholas D; Davis Kenneth
Brain metabolite abnormalities in the white matter of elderly schizophrenic subjects: implication for glial dysfunction.
Biological psychiatry 2007;62(12):1396-404.
2007: Haroutunian Vahram; Davis Kenneth L
Introduction to the special section: Myelin and oligodendrocyte abnormalities in schizophrenia.
The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP) 2007;10(4):499-502.
2007: Haroutunian Vahram; Katsel Pavel; Dracheva Stella; Stewart Daniel G; Davis Kenneth L
Variations in oligodendrocyte-related gene expression across multiple cortical regions: implications for the pathophysiology of schizophrenia.
The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP) 2007;10(4):565-73.
2007: Gill Sandeep K; Ishak Margaret; Dobransky Tomas; Haroutunian Vahram; Davis Kenneth L; Rylett R Jane
82-kDa choline acetyltransferase is in nuclei of cholinergic neurons in human CNS and altered in aging and Alzheimer disease.
Neurobiology of aging 2007;28(7):1028-40.
2007: McCullumsmith Robert E; Gupta Daya; Beneyto Monica; Kreger Emily; Haroutunian Vahram; Davis Kenneth L; Meador-Woodruff James H
Expression of transcripts for myelination-related genes in the anterior cingulate cortex in schizophrenia.
Schizophrenia research 2007;90(1-3):15-27.
2007: Tang Cheuk Y; Friedman Joseph; Shungu Dikoma; Chang Linda; Ernst Thomas; Stewart Daniel; Hajianpour Arash; Carpenter David; Ng Johnny; Mao Xiangling; Hof Patrick R; Buchsbaum Monte S; Davis Kenneth; Gorman Jack M
Correlations between Diffusion Tensor Imaging (DTI) and Magnetic Resonance Spectroscopy (1H MRS) in schizophrenic patients and normal controls.
BMC psychiatry 2007;7():25.
2006: White Leonard; Friedman Joseph I; Bowie Christopher R; Evers Martin; Harvey Philip D; Parrella Michael; Mihaila Emilian; Davis Kenneth L
Long-term outcomes in chronically hospitalized geriatric patients with schizophrenia: retrospective comparison of first generation and second generation antipsychotics.
Schizophrenia research 2006;88(1-3):127-34.
2006: Buchsbaum Monte S; Friedman Joseph; Buchsbaum Bradley R; Chu King-Wai; Hazlett Erin A; Newmark Randall; Schneiderman Jason S; Torosjan Yuliya; Tang Cheuk; Hof Patrick R; Stewart Daniel; Davis Kenneth L; Gorman Jack
Diffusion tensor imaging in schizophrenia.
Biological psychiatry 2006;60(11):1181-7.
2006: Haroutunian Vahram; Katsel Pavel; Dracheva Stella; Davis Kenneth L
The human homolog of the QKI gene affected in the severe dysmyelination "quaking" mouse phenotype: downregulated in multiple brain regions in schizophrenia.
The American journal of psychiatry 2006;163(10):1834-7.
2006: Friedman Joseph I; Davis Kenneth L
Special issue: Molecular mechanisms of schizophrenia.
Biological psychiatry 2006;60(6):527-9.
2006: Georgieva Lyudmila; Moskvina Valentina; Peirce Tim; Norton Nadine; Bray Nicholas J; Jones Lesley; Holmans Peter; Macgregor Stuart; Zammit Stanley; Wilkinson Jennifer; Williams Hywel; Nikolov Ivan; Williams Nigel; Ivanov Dobril; Davis Kenneth L; Haroutunian Vahram; Buxbaum Joseph D; Craddock Nick; Kirov George; Owen Michael J; O'Donovan Michael C
Convergent evidence that oligodendrocyte lineage transcription factor 2 (OLIG2) and interacting genes influence susceptibility to schizophrenia.
Proceedings of the National Academy of Sciences of the United States of America 2006;103(33):12469-74.
2006: Carrión-Baralt Jose R; Smith Christopher J; Rossy-Fullana Enrique; Lewis-Fernández Roberto; Davis Kenneth L; Silverman Jeremy M
Seasonality effects on schizophrenic births in multiplex families in a tropical island.
Psychiatry research 2006;142(1):93-7.
2006: Dracheva Stella; Davis Kenneth L; Chin Benjamin; Woo Derek A; Schmeidler James; Haroutunian Vahram
Myelin-associated mRNA and protein expression deficits in the anterior cingulate cortex and hippocampus in elderly schizophrenia patients.
Neurobiology of disease 2006;21(3):531-40.
2006: Harvey Philip D; Friedman Joseph I; Bowie Christopher; Reichenberg Avraham; McGurk Susan R; Parrella Michael; White Leonard; Davis Kenneth L
Validity and stability of performance-based estimates of premorbid educational functioning in older patients with schizophrenia.
Journal of clinical and experimental neuropsychology 2006;28(2):178-92.
2006: Prohovnik I; Perl D P; Davis K L; Libow L; Lesser G; Haroutunian V
Dissociation of neuropathology from severity of dementia in late-onset Alzheimer disease.
Neurology 2006;66(1):49-55.
2005: Katsel Pavel; Davis Kenneth L; Haroutunian Vahram
Variations in myelin and oligodendrocyte-related gene expression across multiple brain regions in schizophrenia: a gene ontology study.
Schizophrenia research 2005;79(2-3):157-73.
2005: Clinton Sarah M; Ibrahim Hisham M; Frey Kirk A; Davis Kenneth L; Haroutunian Vahram; Meador-Woodruff James H
Dopaminergic abnormalities in select thalamic nuclei in schizophrenia: involvement of the intracellular signal integrating proteins calcyon and spinophilin.
The American journal of psychiatry 2005;162(10):1859-71.
2005: Gupta Daya S; McCullumsmith Robert E; Beneyto Monica; Haroutunian Vahram; Davis Kenneth L; Meador-Woodruff James H
Metabotropic glutamate receptor protein expression in the prefrontal cortex and striatum in schizophrenia.
Synapse (New York, N.Y.) 2005;57(3):123-31.
2005: Katsel P; Davis K L; Gorman J M; Haroutunian V
Variations in differential gene expression patterns across multiple brain regions in schizophrenia.
Schizophrenia research 2005;77(2-3):241-52.
2005: Friedman Joseph I; Ocampo Ramoncito; Elbaz Zeinab; Parrella Michael; White Leonard; Bowler Stephanie; Davis Kenneth L; Harvey Philip D
The effect of citalopram adjunctive treatment added to atypical antipsychotic medications for cognitive performance in patients with schizophrenia.
Journal of clinical psychopharmacology 2005;25(3):237-42.
2005: Bruneau Emile G; McCullumsmith Robert E; Haroutunian Vahram; Davis Kenneth L; Meador-Woodruff James H
Increased expression of glutaminase and glutamine synthetase mRNA in the thalamus in schizophrenia.
Schizophrenia research 2005;75(1):27-34.
2005: Beeri Michal Schnaider; Silverman Jeremy M; Davis Kenneth L; Marin Deborah; Grossman Hillel Z; Schmeidler James; Purohit Dushyant P; Perl Daniel P; Davidson Michael; Mohs Richard C; Haroutunian Vahram
Type 2 diabetes is negatively associated with Alzheimer's disease neuropathology.
The journals of gerontology. Series A, Biological sciences and medical sciences 2005;60(4):471-5.
2005: Katsel Pavel L; Davis Kenneth L; Haroutunian Vahram
Large-scale microarray studies of gene expression in multiple regions of the brain in schizophrenia and Alzheimer's disease.
International review of neurobiology 2005;63():41-82.
2004: Dracheva Stella; Elhakem Sharif L; McGurk Susan R; Davis Kenneth L; Haroutunian Vahram
GAD67 and GAD65 mRNA and protein expression in cerebrocortical regions of elderly patients with schizophrenia.
Journal of neuroscience research 2004;76(4):581-92.
2004: McGurk Susan R; Coleman Thomas; Harvey Philip D; Reichenberg Avraham; White Leonard; Friedman Joseph; Parrella Michael; Davis Kenneth L
Working memory performance in poor outcome schizophrenia: relationship to age and executive functioning.
Journal of clinical and experimental neuropsychology 2004;26(2):153-60.
2004: Ramoz Nicolas; Reichert Jennifer G; Smith Christopher J; Silverman Jeremy M; Bespalova Irina N; Davis Kenneth L; Buxbaum Joseph D
Linkage and association of the mitochondrial aspartate/glutamate carrier SLC25A12 gene with autism.
The American journal of psychiatry 2004;161(4):662-9.
2004: Bowie C R; Harvey P D; Moriarty P J; Parrella M; White L; Davis K L
A comprehensive analysis of verbal fluency deficit in geriatric schizophrenia.
Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists 2004;19(2):289-303.
2004: Siever Larry J; Davis Kenneth L
The pathophysiology of schizophrenia disorders: perspectives from the spectrum.
The American journal of psychiatry 2004;161(3):398-413.
2004: Mueller Helena T; Haroutunian Vahram; Davis Kenneth L; Meador-Woodruff James H
Expression of the ionotropic glutamate receptor subunits and NMDA receptor-associated intracellular proteins in the substantia nigra in schizophrenia.
Brain research. Molecular brain research 2004;121(1-2):60-9.
2004: Bubber Parvesh; Tang Jicheng; Haroutunian Vahram; Xu Hui; Davis Kenneth L; Blass John P; Gibson Gary E
Mitochondrial enzymes in schizophrenia.
Journal of molecular neuroscience : MN 2004;24(2):315-21.
2004: Stewart Daniel G; Davis Kenneth L
Possible contributions of myelin and oligodendrocyte dysfunction to schizophrenia.
International review of neurobiology 2004;59():381-424.
2003: Martin-Ruiz Carmen M; Haroutunian Vahram H; Long Philip; Young Allan H; Davis Kenneth L; Perry Elaine K; Court Jennifer A
Dementia rating and nicotinic receptor expression in the prefrontal cortex in schizophrenia.
Biological psychiatry 2003;54(11):1222-33.
2003: Harvey Philip D; Bertisch Hillary; Friedman Joseph I; Marcus Sue; Parrella Michael; White Leonard; Davis Kenneth L
The course of functional decline in geriatric patients with schizophrenia: cognitive-functional and clinical symptoms as determinants of change.
The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry 2003;11(6):610-9.
2003: Buchsbaum Monte S; Shihabuddin Lina; Brickman Adam M; Miozzo Ruben; Prikryl Radovan; Shaw Robert; Davis Kenneth
Caudate and putamen volumes in good and poor outcome patients with schizophrenia.
Schizophrenia research 2003;64(1):53-62.
2003: Causevic Mirsada; Ramoz Nicolas; Haroutunian Vahram; Davis Kenneth L; Buxbaum Joseph D
Lack of association between the levels of the low-density lipoprotein receptor-related protein (LRP) and either Alzheimer dementia or LRP exon 3 genotype.
Journal of neuropathology and experimental neurology 2003;62(10):999-1005.
2003: Polesskaya Oxana O; Haroutunian Vahram; Davis Kenneth L; Hernandez Ivan; Sokolov Boris P
Novel putative nonprotein-coding RNA gene from 11q14 displays decreased expression in brains of patients with schizophrenia.
Journal of neuroscience research 2003;74(1):111-22.
2003: Davis Kenneth L; Haroutunian Vahram
Global expression-profiling studies and oligodendrocyte dysfunction in schizophrenia and bipolar disorder.
Lancet 2003;362(9386):758.
2003: Mathalon Daniel H; Rapoport Judith L; Davis Kenneth L; Krystal John H
Neurotoxicity, neuroplasticity, and magnetic resonance imaging morphometry.
Archives of general psychiatry 2003;60(8):846-8; author reply 848-9.
2003: Hof Patrick R; Haroutunian Vahram; Friedrich Victor L; Byne William; Buitron Cristian; Perl Daniel P; Davis Kenneth L
Loss and altered spatial distribution of oligodendrocytes in the superior frontal gyrus in schizophrenia.
Biological psychiatry 2003;53(12):1075-85.
2003: Aisen Paul S; Schafer Kimberly A; Grundman Michael; Pfeiffer Eric; Sano Mary; Davis Kenneth L; Farlow Martin R; Jin Shelia; Thomas Ronald G; Thal Leon J;
Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial.
JAMA : the journal of the American Medical Association 2003;289(21):2819-26.
2003: Clinton Sarah M; Haroutunian Vahram; Davis Kenneth L; Meador-Woodruff James H
Altered transcript expression of NMDA receptor-associated postsynaptic proteins in the thalamus of subjects with schizophrenia.
The American journal of psychiatry 2003;160(6):1100-9.
2003: Davis Kenneth L; Stewart Daniel G; Friedman Joseph I; Buchsbaum Monte; Harvey Philip D; Hof Patrick R; Buxbaum Joseph; Haroutunian Vahram
White matter changes in schizophrenia: evidence for myelin-related dysfunction.
Archives of general psychiatry 2003;60(5):443-56.
2003: Serby Michael; Brickman Adam M; Haroutunian Vahram; Purohit Dushyant P; Marin Deborah; Lantz Melinda; Mohs Richard C; Davis Kenneth L
Cognitive burden and excess Lewy-body pathology in the Lewy-body variant of Alzheimer disease.
The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry 2003;11(3):371-4.
2002: Neugroschl Judith; Davis Kenneth L
Biological markers in Alzheimer disease.
The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry 2002;10(6):660-77.
2002: Bowie Christopher R; Harvey Philip D; Moriarty Patrick J; Parrella Michael; White Leonard; Mohs Richard C; Davis Kenneth L
Cognitive assessment of geriatric schizophrenic patients with severe impairment.
Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists 2002;17(7):611-23.
2002: Hof Patrick R; Haroutunian Vahram; Copland Christina; Davis Kenneth L; Buxbaum Joseph D
Molecular and cellular evidence for an oligodendrocyte abnormality in schizophrenia.
Neurochemical research 2002;27(10):1193-200.
2002: Tamminga Carol A; Nemeroff Charles B; Blakely Randy D; Brady Linda; Carter Cameron S; Davis Kenneth L; Dingledine Raymond; Gorman Jack M; Grigoriadis Dimitri E; Henderson David C; B Innis Robert B; Killen John; Laughren Thomas P; McDonald William M; M Murphy Greer M; Paul Steven M; Rudorfer Matthew V; Sausville Edward; Schatzberg Alan F; Scolnick Edward M; Suppes Trisha
Developing novel treatments for mood disorders: accelerating discovery.
Biological psychiatry 2002;52(6):589-609.
2002: Friedman Joseph I; Harvey Philip D; McGurk Susan R; White Leonard; Parrella Michael; Raykov Tenko; Coleman Thomas; Adler David N; Davis Kenneth L
Correlates of change in functional status of institutionalized geriatric schizophrenic patients: focus on medical comorbidity.
The American journal of psychiatry 2002;159(8):1388-94.
2002: Haroutunian Vahram; Davis Kenneth L
Issues and perspectives on brain tissue banking.
Current psychiatry reports 2002;4(4):233-4.
2002: Gluck Martin R; Thomas Rohan G; Davis Kenneth L; Haroutunian Vahram
Implications for altered glutamate and GABA metabolism in the dorsolateral prefrontal cortex of aged schizophrenic patients.
The American journal of psychiatry 2002;159(7):1165-73.
2002: Buchsbaum Monte S; Shihabuddin Lina; Hazlett Erin A; Schröder Johannes; Haznedar Mehmet M; Powchik Peter; Spiegel-Cohen Jacqueline; Wei Tsechung; Singer Melissa B; Davis Kenneth L
Kraepelinian and non-Kraepelinian schizophrenia subgroup differences in cerebral metabolic rate.
Schizophrenia research 2002;55(1-2):25-40.
2002: Friedman Joseph I; Adler David N; Howanitz Evelyn; Harvey Philip D; Brenner Grant; Temporini Humberto; White Leonard; Parrella Michael; Davis Kenneth L
A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia.
Biological psychiatry 2002;51(5):349-57.
2002: Harvey Philip D; Moriarty Patrick J; Bowie Christopher; Friedman Joseph I; Parrella Michael; White Leonard; Davis Kenneth L
Cortical and subcortical cognitive deficits in schizophrenia: convergence of classifications based on language and memory skill areas.
Journal of clinical and experimental neuropsychology 2002;24(1):55-66.
2002: Davis K L
NSAID and Alzheimer's disease; possible answers and new questions.
Molecular psychiatry 2002;7(9):925-6.
2001: Parvathy S; Davies P; Haroutunian V; Purohit D P; Davis K L; Mohs R C; Park H; Moran T M; Chan J Y; Buxbaum J D
Correlation between Abetax-40-, Abetax-42-, and Abetax-43-containing amyloid plaques and cognitive decline.
Archives of neurology 2001;58(12):2025-32.
2001: Smith R E; Haroutunian V; Davis K L; Meador-Woodruff J H
Vesicular glutamate transporter transcript expression in the thalamus in schizophrenia.
Neuroreport 2001;12(13):2885-7.
2001: Friedman J I; Harvey P D; Coleman T; Moriarty P J; Bowie C; Parrella M; White L; Adler D; Davis K L
Six-year follow-up study of cognitive and functional status across the lifespan in schizophrenia: a comparison with Alzheimer's disease and normal aging.
The American journal of psychiatry 2001;158(9):1441-8.
2001: Dracheva S; Marras S A; Elhakem S L; Kramer F R; Davis K L; Haroutunian V
N-methyl-D-aspartic acid receptor expression in the dorsolateral prefrontal cortex of elderly patients with schizophrenia.
The American journal of psychiatry 2001;158(9):1400-10.
2001: Smith R E; Haroutunian V; Davis K L; Meador-Woodruff J H
Expression of excitatory amino acid transporter transcripts in the thalamus of subjects with schizophrenia.
The American journal of psychiatry 2001;158(9):1393-9.
2001: Friedman J I; Adler D N; Temporini H D; Kemether E; Harvey P D; White L; Parrella M; Davis K L
Guanfacine treatment of cognitive impairment in schizophrenia.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2001;25(3):402-9.
2001: Harvey P D; Serper M R; White L; Parrella M J; McGurk S R; Moriarty P J; Bowie C; Vadhan N; Friedman J; Davis K L
The convergence of neuropsychological testing and clinical ratings of cognitive impairment in patients with schizophrenia.
Comprehensive psychiatry 2001;42(4):306-13.
2001: Buxbaum J D; Silverman J M; Smith C J; Kilifarski M; Reichert J; Hollander E; Lawlor B A; Fitzgerald M; Greenberg D A; Davis K L
Evidence for a susceptibility gene for autism on chromosome 2 and for genetic heterogeneity.
American journal of human genetics 2001;68(6):1514-20.
2001: Meador-Woodruff J H; Davis K L; Haroutunian V
Abnormal kainate receptor expression in prefrontal cortex in schizophrenia.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2001;24(5):545-52.
2001: Hakak Y; Walker J R; Li C; Wong W H; Davis K L; Buxbaum J D; Haroutunian V; Fienberg A A
Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia.
Proceedings of the National Academy of Sciences of the United States of America 2001;98(8):4746-51.
2001: Schröder J; Buchsbaum M S; Shihabuddin L; Tang C; Wei T C; Spiegel-Cohen J; Hazlett E A; Abel L; Luu-Hsia C; Ciaravolo T M; Marin D; Davis K L
Patterns of cortical activity and memory performance in Alzheimer's disease.
Biological psychiatry 2001;49(5):426-36.
2001: Schneider L S; Tariot P N; Lyketsos C G; Dagerman K S; Davis K L; Davis S; Hsiao J K; Jeste D V; Katz I R; Olin J T; Pollock B G; Rabins P V; Rosenheck R A; Small G W; Lebowitz B; Lieberman J A
National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer disease trial methodology.
The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry 2001;9(4):346-60.
2001: Bowie C R; Moriarty P J; Harvey P D; Parrella M; White L; Davis K L
Aggression in elderly schizophrenia patients: a comparison of nursing home and state hospital residents.
The Journal of neuropsychiatry and clinical neurosciences 2001;13(3):357-66.
2001: Moriarty P J; Lieber D; Bennett A; White L; Parrella M; Harvey P D; Davis K L
Gender differences in poor outcome patients with lifelong schizophrenia.
Schizophrenia bulletin 2001;27(1):103-13.
2000: Ibrahim H M; Hogg A J; Healy D J; Haroutunian V; Davis K L; Meador-Woodruff J H
Ionotropic glutamate receptor binding and subunit mRNA expression in thalamic nuclei in schizophrenia.
The American journal of psychiatry 2000;157(11):1811-23.
2000: Marin D B; Dugue M; Schmeidler J; Santoro J; Neugroschl J; Zaklad G; Brickman A; Schnur E; Hoblyn J; Davis K L
The Caregiver Activity Survey (CAS): longitudinal validation of an instrument that measures time spent caregiving for individuals with Alzheimer's disease.
International journal of geriatric psychiatry 2000;15(8):680-6.
2000: Haroutunian V; Serby M; Purohit D P; Perl D P; Marin D; Lantz M; Mohs R C; Davis K L
Contribution of Lewy body inclusions to dementia in patients with and without Alzheimer disease neuropathological conditions.
Archives of neurology 2000;57(8):1145-50.
2000: Sokolov B P; Tcherepanov A A; Haroutunian V; Davis K L
Levels of mRNAs encoding synaptic vesicle and synaptic plasma membrane proteins in the temporal cortex of elderly schizophrenic patients.
Biological psychiatry 2000;48(3):184-96.
2000: Silverman J M; Smith C M; Marin D B; Schmeidler J; Birstein S; Lantz M; Davis K L; Mohs R C
Has familial aggregation in Alzheimer's disease been overestimated?
International journal of geriatric psychiatry 2000;15(7):631-7.
2000: Harvey P D; Moriarty P J; Friedman J I; White L; Parrella M; Mohs R C; Davis K L
Differential preservation of cognitive functions in geriatric patients with lifelong chronic schizophrenia: less impairment in reading compared with other skill areas.
Biological psychiatry 2000;47(11):962-8.
2000: Harvey P D; Jacobsen H; Mancini D; Parrella M; White L; Haroutunian V; Davis K L
Clinical, cognitive and functional characteristics of long-stay patients with schizophrenia: a comparison of VA and state hospital patients.
Schizophrenia research 2000;43(1):3-9.
2000: Perry E; Martin-Ruiz C; Lee M; Griffiths M; Johnson M; Piggott M; Haroutunian V; Buxbaum J D; Nãsland J; Davis K; Gotti C; Clementi F; Tzartos S; Cohen O; Soreq H; Jaros E; Perry R; Ballard C; McKeith I; Court J
Nicotinic receptor subtypes in human brain ageing, Alzheimer and Lewy body diseases.
European journal of pharmacology 2000;393(1-3):215-22.
2000: Näslund J; Haroutunian V; Mohs R; Davis K L; Davies P; Greengard P; Buxbaum J D
Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline.
JAMA : the journal of the American Medical Association 2000;283(12):1571-7.
2000: McGurk S R; Moriarty P J; Harvey P D; Parrella M; White L; Davis K L
The longitudinal relationship of clinical symptoms, cognitive functioning, and adaptive life in geriatric schizophrenia.
Schizophrenia research 2000;42(1):47-55.
2000: Aisen P S; Davis K L; Berg J D; Schafer K; Campbell K; Thomas R G; Weiner M F; Farlow M R; Sano M; Grundman M; Thal L J
A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study.
Neurology 2000;54(3):588-93.
2000: Richardson-Burns S M; Haroutunian V; Davis K L; Watson S J; Meador-Woodruff J H
Metabotropic glutamate receptor mRNA expression in the schizophrenic thalamus.
Biological psychiatry 2000;47(1):22-8.
2000: Byne W; Stamu C; White L; Parrella M; Harvey P D; Davis K L
Prevalence and correlates of parkinsonism in an institutionalized population of geriatric patients with chronic schizophrenia.
International journal of geriatric psychiatry 2000;15(1):7-13.
2000: McGurk S R; Moriarty P J; Harvey P D; Parrella M; White L; Friedman J; Davis K L
Relationship of cognitive functioning, adaptive life skills, and negative symptom severity in poor-outcome geriatric schizophrenia patients.
The Journal of neuropsychiatry and clinical neurosciences 2000;12(2):257-64.
1999: Davis K L; Mohs R C; Marin D B; Purohit D P; Perl D P; Lantz M; Austin G; Haroutunian V
Neuropeptide abnormalities in patients with early Alzheimer disease.
Archives of general psychiatry 1999;56(11):981-7.
1999: Friedman J I; Adler D N; Davis K L
The role of norepinephrine in the pathophysiology of cognitive disorders: potential applications to the treatment of cognitive dysfunction in schizophrenia and Alzheimer's disease.
Biological psychiatry 1999;46(9):1243-52.
1999: Friedman J I; Harvey P D; Kemether E; Byne W; Davis K L
Cognitive and functional changes with aging in schizophrenia.
Biological psychiatry 1999;46(7):921-8.
1999: Davis K L; Braff D L; Weinberger D R
Protecting research subjects and psychiatric research: we can do both.
Biological psychiatry 1999;46(6):727-8.
1999: Ehrenkrantz D; Silverman J M; Smith C J; Birstein S; Marin D; Mohs R C; Davis K L
Genetic epidemiological study of maternal and paternal transmission of Alzheimer's disease.
American journal of medical genetics 1999;88(4):378-82.
1999: Haroutunian V; Purohit D P; Perl D P; Marin D; Khan K; Lantz M; Davis K L; Mohs R C
Neurofibrillary tangles in nondemented elderly subjects and mild Alzheimer disease.
Archives of neurology 1999;56(6):713-8.
1999: Amin F; Silverman J M; Siever L J; Smith C J; Knott P J; Davis K L
Genetic antecedents of dopamine dysfunction in schizophrenia.
Biological psychiatry 1999;45(9):1143-50.
1999: Green C R; Marin D B; Mohs R C; Schmeidler J; Aryan M; Fine E; Davis K L
The impact of behavioral impairment of functional ability in Alzheimer's disease.
International journal of geriatric psychiatry 1999;14(4):307-16.
1999: Davis K L; Mohs R C; Marin D; Purohit D P; Perl D P; Lantz M; Austin G; Haroutunian V
Cholinergic markers in elderly patients with early signs of Alzheimer disease.
JAMA : the journal of the American Medical Association 1999;281(15):1401-6.
1999: Byne W; Davis K L
The role of prefrontal cortex in the dopaminergic dysregulation of schizophrenia.
Biological psychiatry 1999;45(6):657-9.
1999: Silverman J M; Smith C J; Marin D B; Birstein S; Mare M; Mohs R C; Davis K L
Identifying families with likely genetic protective factors against Alzheimer disease.
American journal of human genetics 1999;64(3):832-8.
1999: Samuels S C; Silverman J M; Marin D B; Peskind E R; Younki S G; Greenberg D A; Schnur E; Santoro J; Davis K L
CSF beta-amyloid, cognition, and APOE genotype in Alzheimer's disease.
Neurology 1999;52(3):547-51.
1999: Davis K L
Alzheimer's disease: seeking new ways to preserve brain function. Interview by Alice V. Luddington.
Geriatrics 1999;54(2):42-7; quiz 48.
1999: Harvey P D; Parrella M; White L; Mohs R C; Davidson M; Davis K L
Convergence of cognitive and adaptive decline in late-life schizophrenia.
Schizophrenia research 1999;35(1):77-84.
1999: Harvey P D; Silverman J M; Mohs R C; Parrella M; White L; Powchik P; Davidson M; Davis K L
Cognitive decline in late-life schizophrenia: a longitudinal study of geriatric chronically hospitalized patients.
Biological psychiatry 1999;45(1):32-40.
1999: Friedman J I; Temporini H; Davis K L
Pharmacologic strategies for augmenting cognitive performance in schizophrenia.
Biological psychiatry 1999;45(1):1-16.
1998: Healy D J; Haroutunian V; Powchik P; Davidson M; Davis K L; Watson S J; Meador-Woodruff J H
AMPA receptor binding and subunit mRNA expression in prefrontal cortex and striatum of elderly schizophrenics.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 1998;19(4):278-86.
1998: Haroutunian V; Perl D P; Purohit D P; Marin D; Khan K; Lantz M; Davis K L; Mohs R C
Regional distribution of neuritic plaques in the nondemented elderly and subjects with very mild Alzheimer disease.
Archives of neurology 1998;55(9):1185-91.
1998: Marin D B; Breuer B; Marin M L; Silverman J; Schmeidler J; Greenberg D; Flynn S; Mare M; Lantz M; Libow L; Neufeld R; Altstiel L; Davis K L; Mohs R C
The relationship between apolipoprotein E, dementia, and vascular illness.
Atherosclerosis 1998;140(1):173-80.
1998: Harvey P D; Howanitz E; Parrella M; White L; Davidson M; Mohs R C; Hoblyn J; Davis K L
Symptoms, cognitive functioning, and adaptive skills in geriatric patients with lifelong schizophrenia: a comparison across treatment sites.
The American journal of psychiatry 1998;155(8):1080-6.
1998: Byne W; White L; Parella M; Adams R; Harvey P D; Davis K L
Tardive dyskinesia in a chronically institutionalized population of elderly schizophrenic patients: prevalence and association with cognitive impairment.
International journal of geriatric psychiatry 1998;13(7):473-9.
1998: Davis K L; Buchsbaum M S; Shihabuddin L; Spiegel-Cohen J; Metzger M; Frecska E; Keefe R S; Powchik P
Ventricular enlargement in poor-outcome schizophrenia.
Biological psychiatry 1998;43(11):783-93.
1998: Samuels S C; Davis K L
Experimental approaches to cognitive disturbance in Alzheimer's disease.
Harvard review of psychiatry 1998;6(1):11-22.
1998: Gabriel S M; Marin D B; Aisen P S; Lantz M; Altstiel L D; Davis K L; Mohs R C
Association of elevated alpha 1-antichymotrypsin with cognitive impairment in a prospective study of the very old.
The American journal of psychiatry 1998;155(5):698-700.
1998: Purohit D P; Perl D P; Haroutunian V; Powchik P; Davidson M; Davis K L
Alzheimer disease and related neurodegenerative diseases in elderly patients with schizophrenia: a postmortem neuropathologic study of 100 cases.
Archives of general psychiatry 1998;55(3):205-11.
1998: Knopman D; Schneider L; Davis K; Gracon S; Smith F
Long-term tacrine treatment effects.
Neurology 1998;50(2):567-8.
1998: Silverman J M; Smith C J; Guo S L; Mohs R C; Siever L J; Davis K L
Lateral ventricular enlargement in schizophrenic probands and their siblings with schizophrenia-related disorders.
Biological psychiatry 1998;43(2):97-106.
1998: Davis K L
Future therapeutic approaches to Alzheimer's disease.
The Journal of clinical psychiatry 1998;59 Suppl 11():14-6.
1998: Powchik P; Davidson M; Haroutunian V; Gabriel S M; Purohit D P; Perl D P; Harvey P D; Davis K L
Postmortem studies in schizophrenia.
Schizophrenia bulletin 1998;24(3):325-41.
1997: Meador-Woodruff J H; Haroutunian V; Powchik P; Davidson M; Davis K L; Watson S J
Dopamine receptor transcript expression in striatum and prefrontal and occipital cortex. Focal abnormalities in orbitofrontal cortex in schizophrenia.
Archives of general psychiatry 1997;54(12):1089-95.
1997: Marin D B; Green C R; Schmeidler J; Harvey P D; Lawlor B A; Ryan T M; Aryan M; Davis K L; Mohs R C
Noncognitive disturbances in Alzheimer's disease: frequency, longitudinal course, and relationship to cognitive symptoms.
Journal of the American Geriatrics Society 1997;45(11):1331-8.
1997: Davis K L; Marin D B; Kane R; Patrick D; Peskind E R; Raskind M A; Puder K L
The Caregiver Activity Survey (CAS): development and validation of a new measure for caregivers of persons with Alzheimer's disease.
International journal of geriatric psychiatry 1997;12(10):978-88.
1997: Gabriel S M; Haroutunian V; Powchik P; Honer W G; Davidson M; Davies P; Davis K L
Increased concentrations of presynaptic proteins in the cingulate cortex of subjects with schizophrenia.
Archives of general psychiatry 1997;54(6):559-66.
1997: Haroutunian V; Greig N; Pei X F; Utsuki T; Gluck R; Acevedo L D; Davis K L; Wallace W C
Pharmacological modulation of Alzheimer's beta-amyloid precursor protein levels in the CSF of rats with forebrain cholinergic system lesions.
Brain research. Molecular brain research 1997;46(1-2):161-8.
1997: Aisen P S; Davis K L
The search for disease-modifying treatment for Alzheimer's disease.
Neurology 1997;48(5 Suppl 6):S35-41.
1997: Li G; Aryan M; Silverman J M; Haroutunian V; Perl D P; Birstein S; Lantz M; Marin D B; Mohs R C; Davis K L
The validity of the family history method for identifying Alzheimer disease.
Archives of neurology 1997;54(5):634-40.
1997: Li G; Silverman J M; Smith C J; Zaccario M L; Wentzel-Bell C; Siever L J; Mohs R C; Davis K L
Validity of the family history method for identifying schizophrenia-related disorders.
Psychiatry research 1997;70(1):39-48.
1997: Keefe R S; Silverman J M; Mohs R C; Siever L J; Harvey P D; Friedman L; Roitman S E; DuPre R L; Smith C J; Schmeidler J; Davis K L
Eye tracking, attention, and schizotypal symptoms in nonpsychotic relatives of patients with schizophrenia.
Archives of general psychiatry 1997;54(2):169-76.
1997: Harvey P D; Lombardi J; Leibman M; Parrella M; White L; Powchik P; Mohs R C; Davidson M; Davis K L
Age-related differences in formal thought disorder in chronically hospitalized schizophrenic patients: a cross-sectional study across nine decades.
The American journal of psychiatry 1997;154(2):205-10.
1997: Samuels S C; Davis K L
A risk-benefit assessment of tacrine in the treatment of Alzheimer's disease.
Drug safety : an international journal of medical toxicology and drug experience 1997;16(1):66-77.
1996: Harvey P D; Davidson M; White L; Keefe R S; Hirschowitz J; Mohs R C; Davis K L
Empirical evaluation of the factorial structure of clinical symptoms in schizophrenia: effects of typical neuroleptics on the brief psychiatric rating scale.
Biological psychiatry 1996;40(8):755-60.
1996: Shihabuddin L; Silverman J M; Buchsbaum M S; Seiver L J; Luu C; Germans M K; Metzger M; Mohs R C; Smith C J; Spiegel-Cohen J; Davis K L
Ventricular enlargement associated with linkage marker for schizophrenia-related disorders in one pedigree.
Molecular psychiatry 1996;1(3):215-22.
1996: Aisen P S; Marin D; Altstiel L; Goodwin C; Baruch B; Jacobson R; Ryan T; Davis K L
A pilot study of prednisone in Alzheimer's disease.
Dementia (Basel, Switzerland) 1996;7(4):201-6.
1996: Meador-Woodruff J H; Damask S P; Wang J; Haroutunian V; Davis K L; Watson S J
Dopamine receptor mRNA expression in human striatum and neocortex.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 1996;15(1):17-29.
1996: Knopman D; Schneider L; Davis K; Talwalker S; Smith F; Hoover T; Gracon S
Long-term tacrine (Cognex) treatment: effects on nursing home placement and mortality, Tacrine Study Group.
Neurology 1996;47(1):166-77.
1996: Keefe R S; Frescka E; Apter S H; Davidson M; Macaluso J M; Hirschowitz J; Davis K L
Clinical characteristics of Kraepelinian schizophrenia: replication and extension of previous findings.
The American journal of psychiatry 1996;153(6):806-11.
1996: Silverman J M; Greenberg D A; Altstiel L D; Siever L J; Mohs R C; Smith C J; Zhou G; Hollander T E; Yang X P; Kedache M; Li G; Zaccario M L; Davis K L
Evidence of a locus for schizophrenia and related disorders on the short arm of chromosome 5 in a large pedigree.
American journal of medical genetics 1996;67(2):162-71.
1996: Davis K L
Progress in understanding the pathogenesis of Alzheimer's disease.
Molecular psychiatry 1996;1(1):11-2.
1996: Serby M; Mohan C; Aryan M; Williams L; Mohs R C; Davis K L
Olfactory identification deficits in relatives of Alzheimer's disease patients.
Biological psychiatry 1996;39(5):375-7.
1996: Gabriel S M; Davidson M; Haroutunian V; Powchik P; Bierer L M; Purohit D P; Perl D P; Davis K L
Neuropeptide deficits in schizophrenia vs. Alzheimer's disease cerebral cortex.
Biological psychiatry 1996;39(2):82-91.
1996: Davis K L
Issues in accelerating the pace of development for neuroprotective agents.
Alzheimer disease and associated disorders 1996;10 Suppl 1():36-7.
1996: Li G; Silverman J M; Altstiel L D; Haroutunian V; Perl D P; Purohit D; Birstein S; Lantz M; Mohs R C; Davis K L
Apolipoprotein E-epsilon 4 allele and familial risk in Alzheimer's disease.
Genetic epidemiology 1996;13(3):285-98.
1995: Marin D B; Bierer L M; Lawlor B A; Ryan T M; Jacobson R; Schmeidler J; Mohs R C; Davis K L
L-deprenyl and physostigmine for the treatment of Alzheimer's disease.
Psychiatry research 1995;58(3):181-9.
1995: Keefe R S; Roitman S E; Harvey P D; Blum C S; DuPre R L; Prieto D M; Davidson M; Davis K L
A pen-and-paper human analogue of a monkey prefrontal cortex activation task: spatial working memory in patients with schizophrenia.
Schizophrenia research 1995;17(1):25-33.
1995: Lawlor B A; Bierer L M; Ryan T M; Schmeidler J; Knott P J; Williams L L; Mohs R C; Davis K L
Plasma 3-methoxy-4-hydroxyphenylglycol (MHPG) and clinical symptoms in Alzheimer's disease.
Biological psychiatry 1995;38(3):185-8.
1995: Wallace W C; Lieberburg I; Schenk D; Vigo-Pelfrey C; Davis K L; Haroutunian V
Chronic elevation of secreted amyloid precursor protein in subcortically lesioned rats, and its exacerbation in aged rats.
The Journal of neuroscience : the official journal of the Society for Neuroscience 1995;15(7 Pt 1):4896-905.
1995: Lawlor B A; Ryan T M; Bierer L M; Schmeidler J; Haroutunian V; Mohs R; Davis K L
Lack of association between clinical symptoms and postmortem indices of brain serotonin function in Alzheimer's disease.
Biological psychiatry 1995;37(12):895-6.
1995: Li G; Silverman J M; Smith C J; Zaccario M L; Schmeidler J; Mohs R C; Davis K L
Age at onset and familial risk in Alzheimer's disease.
The American journal of psychiatry 1995;152(3):424-30.
1995: Davis K L; Powchik P
Tacrine.
Lancet 1995;345(8950):625-30.
1995: Bierer L M; Haroutunian V; Gabriel S; Knott P J; Carlin L S; Purohit D P; Perl D P; Schmeidler J; Kanof P; Davis K L
Neurochemical correlates of dementia severity in Alzheimer's disease: relative importance of the cholinergic deficits.
Journal of neurochemistry 1995;64(2):749-60.
1995: Bierer L M; Hof P R; Purohit D P; Carlin L; Schmeidler J; Davis K L; Perl D P
Neocortical neurofibrillary tangles correlate with dementia severity in Alzheimer's disease.
Archives of neurology 1995;52(1):81-8.
1995: Altstiel L D; Lawlor B; Mohs R; Schmeidler J; Dalton A; Mehta P; Davis K
Elevated alpha 1-antichymotrypsin serum levels in a subset of nondemented first-degree relatives of Alzheimer's disease patients.
Dementia (Basel, Switzerland) 1995;6(1):17-20.
1994: Stern R G; Kahn R S; Davidson M; Nora R M; Davis K L
Early response to clozapine in schizophrenia.
The American journal of psychiatry 1994;151(12):1817-8.
1994: Lawlor B A; Ryan T M; Schmeidler J; Mohs R C; Davis K L
Clinical symptoms associated with age at onset in Alzheimer's disease.
The American journal of psychiatry 1994;151(11):1646-9.
1994: Bierer L M; Aisen P S; Davidson M; Ryan T M; Schmeidler J; Davis K L
A pilot study of clonidine plus physostigmine in Alzheimer's disease.
Dementia (Basel, Switzerland) 1994;5(5):243-6.
1994: Aisen P S; Davis K L
Inflammatory mechanisms in Alzheimer's disease: implications for therapy.
The American journal of psychiatry 1994;151(8):1105-13.
1994: Silverman J M; Li G; Zaccario M L; Smith C J; Schmeidler J; Mohs R C; Davis K L
Patterns of risk in first-degree relatives of patients with Alzheimer's disease.
Archives of general psychiatry 1994;51(7):577-86.
1994: Keefe R S; Silverman J M; Roitman S E; Harvey P D; Duncan M A; Alroy D; Siever L J; Davis K L; Mohs R C
Performance of nonpsychotic relatives of schizophrenic patients on cognitive tests.
Psychiatry research 1994;53(1):1-12.
1994: Kahn R S; Davidson M; Siever L J; Sevy S; Davis K L
Clozapine treatment and its effect on neuroendocrine responses induced by the serotonin agonist, m-chlorophenylpiperazine.
Biological psychiatry 1994;35(12):909-12.
1994: Haroutunian V; Davidson M; Kanof P D; Perl D P; Powchik P; Losonczy M; McCrystal J; Purohit D P; Bierer L M; Davis K L
Cortical cholinergic markers in schizophrenia.
Schizophrenia research 1994;12(2):137-44.
1994: Stern R G; Mohs R C; Davidson M; Schmeidler J; Silverman J; Kramer-Ginsberg E; Searcey T; Bierer L; Davis K L
A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration.
The American journal of psychiatry 1994;151(3):390-6.
1994: Perry E K; Haroutunian V; Davis K L; Levy R; Lantos P; Eagger S; Honavar M; Dean A; Griffiths M; McKeith I G
Neocortical cholinergic activities differentiate Lewy body dementia from classical Alzheimer's disease.
Neuroreport 1994;5(7):747-9.
1994: Miller A H; Sastry G; Speranza A J; Lawlor B A; Mohs R C; Ryan T M; Gabriel S M; Serby M; Schmeidler J; Davis K L
Lack of association between cortisol hypersecretion and nonsuppression on the DST in patients with Alzheimer's disease.
The American journal of psychiatry 1994;151(2):267-70.
1994: Kahn R S; Harvey P D; Davidson M; Keefe R S; Apter S; Neale J M; Mohs R C; Davis K L
Neuropsychological correlates of central monoamine function in chronic schizophrenia: relationship between CSF metabolites and cognitive function.
Schizophrenia research 1994;11(3):217-24.
1994: Davis K L
Acceleration of the development of a treatment for Alzheimer's disease.
Neurobiology of aging 1994;15 Suppl 2():S55-6.
1993: Bierer L M; Knott P J; Schmeidler J M; Marin D B; Ryan T M; Haroutunian V; Purohit D P; Perl D P; Mohs R C; Davis K L
Post-mortem examination of dopaminergic parameters in Alzheimer's disease: relationship to noncognitive symptoms.
Psychiatry research 1993;49(3):211-7.
1993: Schmauss C; Haroutunian V; Davis K L; Davidson M
Selective loss of dopamine D3-type receptor mRNA expression in parietal and motor cortices of patients with chronic schizophrenia.
Proceedings of the National Academy of Sciences of the United States of America 1993;90(19):8942-6.
1993: Kahn R S; Davidson M; Siever L; Gabriel S; Apter S; Davis K L
Serotonin function and treatment response to clozapine in schizophrenic patients.
The American journal of psychiatry 1993;150(9):1337-42.
1993: Wallace W; Ahlers S T; Gotlib J; Bragin V; Sugar J; Gluck R; Shea P A; Davis K L; Haroutunian V
Amyloid precursor protein in the cerebral cortex is rapidly and persistently induced by loss of subcortical innervation.
Proceedings of the National Academy of Sciences of the United States of America 1993;90(18):8712-6.
1993: Kahn R S; Davidson M; Knott P; Stern R G; Apter S; Davis K L
Effect of neuroleptic medication on cerebrospinal fluid monoamine metabolite concentrations in schizophrenia. Serotonin-dopamine interactions as a target for treatment.
Archives of general psychiatry 1993;50(8):599-605.
1993: Green C R; Mohs R C; Schmeidler J; Aryan M; Davis K L
Functional decline in Alzheimer's disease: a longitudinal study.
Journal of the American Geriatrics Society 1993;41(6):654-61.
1993: Gabriel S M; Bierer L M; Harotunian V; Purohit D P; Perl D P; Davis K L
Widespread deficits in somatostatin but not neuropeptide Y concentrations in Alzheimer's disease cerebral cortex.
Neuroscience letters 1993;155(1):116-20.
1993: Silverman J M; Siever L J; Horvath T B; Coccaro E F; Klar H; Davidson M; Pinkham L; Apter S H; Mohs R C; Davis K L
Schizophrenia-related and affective personality disorder traits in relatives of probands with schizophrenia and personality disorders.
The American journal of psychiatry 1993;150(3):435-42.
1993: Davidson M; Kahn R S; Stern R G; Hirschowitz J; Apter S; Knott P; Davis K L
Treatment with clozapine and its effect on plasma homovanillic acid and norepinephrine concentrations in schizophrenia.
Psychiatry research 1993;46(2):151-63.
1993: Purohit D P; Davidson M; Perl D P; Powchik P; Haroutunian V H; Bierer L M; McCrystal J; Losonczy M; Davis K L
Severe cognitive impairment in elderly schizophrenic patients: a clinicopathological study.
Biological psychiatry 1993;33(4):255-60.
1993: Omar R; Pappolla M; Argani I; Davis K
Acid phosphatase activity in senile plaques and cerebrospinal fluid of patients with Alzheimer's disease.
Archives of pathology & laboratory medicine 1993;117(2):166-9.
1993: Bierer L M; Aisen P S; Davidson M; Ryan T M; Stern R G; Schmeidler J; Davis K L
A pilot study of oral physostigmine plus yohimbine in patients with Alzheimer disease.
Alzheimer disease and associated disorders 1993;7(2):98-104.
1992: Keefe R S; Harvey P D; Lenzenweger M F; Davidson M; Apter S H; Schmeidler J; Mohs R C; Davis K L
Empirical assessment of the factorial structure of clinical symptoms in schizophrenia: negative symptoms.
Psychiatry research 1992;44(2):153-65.
1992: Davis K L; Thal L J; Gamzu E R; Davis C S; Woolson R F; Gracon S I; Drachman D A; Schneider L S; Whitehouse P J; Hoover T M
A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group.
The New England journal of medicine 1992;327(18):1253-9.
1992: Tsuboyama G K; Gabriel S S; Davis B M; Davison M; Lawlor B A; Ware K; Davis K L; Mohs R C
Neuroendocrine dysfunction in Alzheimer's disease: results following TRH stimulation.
Biological psychiatry 1992;32(2):195-8.
1992: Stern R G; Mohs R C; Bierer L M; Silverman J M; Schmeidler J; Davidson M; Davis K L
Deterioration on the Blessed test in Alzheimer's disease: longitudinal data and their implications for clinical trials and identification of subtypes.
Psychiatry research 1992;42(2):101-10.
1992: Lawlor B A; Tsuboyama G; Ryan T; Mohs R C; Davis B M; Davidson M; Gabriel S; Davis K L
Agitation and postdexamethasone cortisol levels in Alzheimer's disease.
The American journal of psychiatry 1992;149(4):546-8.
1992: Davis K
The scintigraphic appearance of Alzheimer's disease: a prospective study using technetium-99m-HMPAO SPECT.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1992;33(2):312.
1992: Kahn R S; Davidson M; Hirschowitz J; Stern R G; Davis B M; Gabriel S; Moore C; Davis K L
Nocturnal growth hormone secretion in schizophrenic patients and healthy subjects.
Psychiatry research 1992;41(2):155-61.
1992: Lawlor B A; Davis K L
Does modulation of glutamatergic function represent a viable therapeutic strategy in Alzheimer's disease?
Biological psychiatry 1992;31(4):337-50.
1992: Amin F; Davidson M; Davis K L
Homovanillic acid measurement in clinical research: a review of methodology.
Schizophrenia bulletin 1992;18(1):123-48.
1992: Davidson M; Kahn R S; Stern R G; Harvey P D; Keefe R; Knott P; Apter S; Webster L; Davis K L
Measurements of plasma homovanillic acid in schizophrenic patients.
Clinical neuropharmacology 1992;15 Suppl 1 Pt A():521A-522A.
1991: Siever L J; Davis K L
A psychobiological perspective on the personality disorders.
The American journal of psychiatry 1991;148(12):1647-58.
1991: Davis K L; Kahn R S; Ko G; Davidson M
Dopamine in schizophrenia: a review and reconceptualization.
The American journal of psychiatry 1991;148(11):1474-86.
1991: Davidson M; Kahn R S; Knott P; Kaminsky R; Cooper M; DuMont K; Apter S; Davis K L
Effects of neuroleptic treatment on symptoms of schizophrenia and plasma homovanillic acid concentrations.
Archives of general psychiatry 1991;48(10):910-3.
1991: Harvey P D; Davidson M; Powchik P; Schmeidler J; McQueeney R; Kaminsky R; Davis K L
Time course and clinical predictors of treatment response in schizophrenia.
Schizophrenia research 1991;5(2):161-6.
1991: Siever L J; Amin F; Coccaro E F; Bernstein D; Kavoussi R J; Kalus O; Horvath T B; Warne P; Davidson M; Davis K L
Plasma homovanillic acid in schizotypal personality disorder.
The American journal of psychiatry 1991;148(9):1246-8.
1991: Harvey P D; Putnam K M; Davidson M; Kahn R S; Powchik P; McQueeney R; Keefe R S; Davis K L
Brief neuroleptic discontinuation and clinical symptoms in Kraepelinian and non-Kraepelinian chronic schizophrenic patients.
Psychiatry research 1991;38(3):285-92.
1991: Wallace W C; Bragin V; Robakis N K; Sambamurti K; VanderPutten D; Merril C R; Davis K L; Santucci A C; Haroutunian V
Increased biosynthesis of Alzheimer amyloid precursor protein in the cerebral cortex of rats with lesions of the nucleus basalis of Meynert.
Brain research. Molecular brain research 1991;10(2):173-8.
1991: Keefe R S; Lobel D S; Mohs R C; Silverman J M; Harvey P D; Davidson M; Losonczy M F; Davis K L
Diagnostic issues in chronic schizophrenia: kraepelinian schizophrenia, undifferentiated schizophrenia, and state-independent negative symptoms.
Schizophrenia research 1991;4(2):71-9.
1991: Kanof P D; Mohs R C; Gross J; Davidson M; Bierer L M; Davis K L
Platelet phospholipid synthesis in Alzheimer's disease.
Neurobiology of aging 1991;12(1):65-9.
1991: Davidson M; Kahn R S; Powchik P; Warne P; Losonczy M F; Kaminsky R; Apter S; Jaff S; Davis K L
Changes in plasma homovanillic acid concentrations in schizophrenic patients following neuroleptic discontinuation.
Archives of general psychiatry 1991;48(1):73-6.
1991: Kahn R S; Davidson M; Kanof P; McQueeney R T; Singh R R; Davis K L
Effects of indomethacin on plasma homovanillic acid concentration in normal subjects: a study of prostaglandin-dopamine interactions.
Psychopharmacology 1991;103(1):95-8.
1991: Santucci A C; Haroutunian V; Davis K L
Pharmacological alleviation of combined cholinergic/noradrenergic lesion-induced memory deficits in rats.
Clinical neuropharmacology 1991;14 Suppl 1():S1-8.
1990: Zemishlany Z; Patterson D; Davis K L; Hards R G
Glycinamide ribonucleotide synthetase activity in lymphocytes from patients with Alzheimer's disease and normal controls.
Biological psychiatry 1990;28(12):1058-60.
1990: Harvey P D; Keefe R S; Moskowitz J; Putnam K M; Mohs R C; Davis K L
Attentional markers of vulnerability to schizophrenia: performance of medicated and unmedicated patients and normals.
Psychiatry research 1990;33(2):179-88.
1990: Siever L J; Silverman J M; Horvath T B; Klar H; Coccaro E; Keefe R S; Pinkham L; Rinaldi P; Mohs R C; Davis K L
Increased morbid risk for schizophrenia-related disorders in relatives of schizotypal personality disordered patients.
Archives of general psychiatry 1990;47(7):634-40.
1990: Davidson M; Harvey P D; Bergman R L; Powchik P; Kaminsky R; Losonczy M F; Davis K L
Effects of the D-1 agonist SKF-38393 combined with haloperidol in schizophrenic patients.
Archives of general psychiatry 1990;47(2):190-1.
1990: Haroutunian V; Kanof P D; Tsuboyama G; Davis K L
Restoration of cholinomimetic activity by clonidine in cholinergic plus noradrenergic lesioned rats.
Brain research 1990;507(2):261-6.
1990: Bierer L M; Perl D P; Haroutunian V; Mohs R C; Davis K L
Neurofibrillary tangles, Alzheimer's disease and Lewy bodies.
Lancet 1990;335(8682):163.
1990: Gamzu E R; Thal L J; Davis K L
Therapeutic trials using tacrine and other cholinesterase inhibitors.
Advances in neurology 1990;51():241-5.
1990: Haroutunian V; Santucci A C; Davis K L
Implications of multiple transmitter system lesions for cholinomimetic therapy in Alzheimer's disease.
Progress in brain research 1990;84():333-46.
1989: Greenwald B S; Kramer-Ginsberg E; Marin D B; Laitman L B; Hermann C K; Mohs R C; Davis K L
Dementia with coexistent major depression.
The American journal of psychiatry 1989;146(11):1472-8.
1989: Haroutunian V; Kanof P D; Davis K L
Interactions of forebrain cholinergic and somatostatinergic systems in the rat.
Brain research 1989;496(1-2):98-104.
1989: Davis K L
Toward a therapeutic strategy based on amyloid precursor protein: unanswered questions.
Neurobiology of aging 1989;10(5):475-6; discussion 477-8.
1989: Shutske G M; Pierrat F A; Kapples K J; Cornfeldt M L; Szewczak M R; Huger F P; Bores G M; Haroutunian V; Davis K L
9-Amino-1,2,3,4-tetrahydroacridin-1-ols: synthesis and evaluation as potential Alzheimer's disease therapeutics.
Journal of medicinal chemistry 1989;32(8):1805-13.
1989: Pappolla M A; Omar R; Saran B; Andorn A; Suarez M; Pavia C; Weinstein A; Shank D; Davis K; Burgdorfer W
Concurrent neuroborreliosis and Alzheimer's disease: analysis of the evidence.
Human pathology 1989;20(8):753-7.
1989: Coccaro E F; Siever L J; Klar H M; Maurer G; Cochrane K; Cooper T B; Mohs R C; Davis K L
Serotonergic studies in patients with affective and personality disorders. Correlates with suicidal and impulsive aggressive behavior.
Archives of general psychiatry 1989;46(7):587-99.
1989: Haroutunian V; Kanof P D; Davis K L
Attenuation of nucleus basalis of Meynert lesion-induced cholinergic deficits by nerve growth factor.
Brain research 1989;487(1):200-3.
1989: Keefe R S; Mohs R C; Losonczy M F; Davidson M; Silverman J M; Horvath T B; Davis K L
Premorbid sociosexual functioning and long-term outcome in schizophrenia.
The American journal of psychiatry 1989;146(2):206-11.
1989: Kanof P D; Coccaro E F; Johns C A; Davidson M; Siever L J; Davis K L
Cyclic-AMP production by polymorphonuclear leukocytes in psychiatric disorders.
Biological psychiatry 1989;25(4):413-20.
1989: Harvey P D; Davidson M; Davis K L; Bastiaens L
Change in subtype presentation in schizophrenics.
Comprehensive psychiatry 1989;30(1):114-6.
1989: Faull K F; Berger P A; Kilkowski J; Anderson P J; Kraemer H; Davis K L; Barchas J D
Corrections to a 1980 article on CSF monoamine metabolites.
The American journal of psychiatry 1989;146(1):118.
1989: Keefe R S; Siever L J; Mohs R C; Peterson A E; Mahon T R; Bergman R L; Davis K L
Eye tracking, schizophrenic symptoms, and schizotypal personality disorder.
European archives of psychiatry and neurological sciences 1989;239(1):39-42.
1989: Santucci A C; Haroutunian V; Tsuboyama G K; Kanof P D; Davis K L
Therapeutics of Alzheimer's disease for clinical and pre-clinical issues.
Progress in clinical and biological research 1989;317():1111-20.
1989: Davidson M; Bierer L M; Kaminsky R; Ryan T M; Davis K L
Combined administration of physostigmine and clonidine to patients with dementia of the Alzheimer type: a pilot safety study.
Alzheimer disease and associated disorders 1989;3(4):224-7.
1989: Silverman J M; Keefe R S; Mohs R C; Davis K L
A study of the reliability of the family history method in genetic studies of Alzheimer disease.
Alzheimer disease and associated disorders 1989;3(4):218-23.
1989: Halperin R; Guerin J J; Davis K L
Regional differences in the induction of behavioral supersensitivity by prolonged treatment with atypical neuroleptics.
Psychopharmacology 1989;98(3):386-91.
1988: Davis K L; Davidson M; Yang R K; Davis B M; Siever L J; Mohs R C; Ryan T; Coccaro E; Bierer L; Targum S D
CSF somatostatin in Alzheimer's disease, depressed patients, and control subjects.
Biological psychiatry 1988;24(6):710-2.
1988: Breitner J C; Murphy E A; Silverman J M; Mohs R C; Davis K L
Age-dependent expression of familial risk in Alzheimer's disease.
American journal of epidemiology 1988;128(3):536-48.
1988: Davidson M; Davis B M; Bastiaens L; Macaluso J; Aryan M; Ryan T; Davis K L
Growth hormone response to edrophonium in patients with Alzheimer's disease and normal control subjects.
The American journal of psychiatry 1988;145(8):1007-9.
1988: Shutske G M; Pierrat F A; Cornfeldt M L; Szewczak M R; Huger F P; Bores G M; Haroutunian V; Davis K L
(+/-)-9-Amino-1,2,3,4-tetrahydroacridin-1-ol. A potential Alzheimer's disease therapeutic of low toxicity.
Journal of medicinal chemistry 1988;31(7):1278-9.
1988: Davidson M; Davis K L
A comparison of plasma homovanillic acid concentrations in schizophrenic patients and normal controls.
Archives of general psychiatry 1988;45(6):561-3.
1988: Coccaro E F; Siever L J; Kourides I A; Adan F; Campbell G; Davis K L
Central serotoninergic stimulation by fenfluramine challenge does not affect plasma thyrotropin-stimulating hormone levels in man.
Neuroendocrinology 1988;47(4):273-6.
1988: Davidson M; Bastiaens L; Davis B M; Shah M B; Davis K L
Endocrine changes in Alzheimer's disease.
Endocrinology and metabolism clinics of North America 1988;17(1):149-57.
1988: Davidson M; Zemishlany Z; Mohs R C; Horvath T B; Powchik P; Blass J P; Davis K L
4-Aminopyridine in the treatment of Alzheimer's disease.
Biological psychiatry 1988;23(5):485-90.
1988: Breitner J C; Silverman J M; Mohs R C; Davis K L
Familial aggregation in Alzheimer's disease: comparison of risk among relatives of early-and late-onset cases, and among male and female relatives in successive generations.
Neurology 1988;38(2):207-12.
1988: Davidson M; Bastiaens L; Davis B M; Shah M B; Davis K L
Endocrine changes in Alzheimer's disease.
Neurologic clinics 1988;6(1):149-57.
1988: Ponte P; Gonzalez-DeWhitt P; Schilling J; Miller J; Hsu D; Greenberg B; Davis K; Wallace W; Lieberburg I; Fuller F
A new A4 amyloid mRNA contains a domain homologous to serine proteinase inhibitors.
Nature 1988;331(6156):525-7.
1988: Davidson M; Powchik P; Davis K L
Pisa syndrome in Alzheimer's disease.
Biological psychiatry 1988;23(2):213.
1988: Sorokin J E; Giordani B; Mohs R C; Losonczy M F; Davidson M; Siever L J; Ryan T A; Davis K L
Memory impairment in schizophrenic patients with tardive dyskinesia.
Biological psychiatry 1988;23(2):129-35.
1988: Kanof P D; Johns C A; Davidson M; Siever L J; Coccaro E F; Davis K L
Platelet alpha 2-adrenergic receptor function in psychiatric disorders.
Psychiatry research 1988;23(1):11-22.
1988: Kramer-Ginsberg E; Mohs R C; Aryan M; Lobel D; Silverman J; Davidson M; Davis K L
Clinical predictors of course for Alzheimer patients in a longitudinal study: a preliminary report.
Psychopharmacology bulletin 1988;24(3):458-62.
1988: Haroutunian V; Knott P; Davis K L
Effects of mesocortical dopaminergic lesions upon subcortical dopaminergic function.
Psychopharmacology bulletin 1988;24(3):341-4.
1988: Friedhoff A J; Pickar D; Axelrod J; Creese I; Davis K L; Gallagher D W; Greengard P; Housman D; Maas J W; Richelson E
Neurochemistry and neuropharmacology.
Schizophrenia bulletin 1988;14(3):399-412.
1988: Keefe R S; Mohs R C; Davidson M; Losonczy M F; Silverman J M; Lesser J C; Horvath T B; Davis K L
Kraepelinian schizophrenia: a subgroup of schizophrenia?
Psychopharmacology bulletin 1988;24(1):56-61.
1987: Davidson M; Losonczy M F; Mohs R C; Lesser J C; Powchik P; Freed L B; Davis B M; Mykytyn V V; Davis K L
Effects of debrisoquin and haloperidol on plasma homovanillic acid concentration in schizophrenic patients.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 1987;1(1):17-23.
1987: Zemishlany Z; Davidson M; Davis K L
[Cholinergic agents in the treatment of Alzheimer's disease]
Harefuah 1987;113(12):401-4.
1987: Kanof P D; Davidson M; Johns C A; Mohs R C; Davis K L
Clinical correlates of platelet prostaglandin receptor subsensitivity in schizophrenia.
The American journal of psychiatry 1987;144(12):1556-60.
1987: Coccaro E F; Siever L J; Klar H; Rubenstein K; Benjamin E; Davis K L
Diminished prolactin responses to repeated fenfluramine challenge in man.
Psychiatry research 1987;22(3):257-9.
1987: Silverman J M; Mohs R C; Davidson M; Losonczy M F; Keefe R S; Breitner J C; Sorokin J E; Davis K L
Familial schizophrenia and treatment response.
The American journal of psychiatry 1987;144(10):1271-6.
1987: Hollander E; Davidson M; Mohs R C; Horvath T B; Davis B M; Zemishlany Z; Davis K L
RS 86 in the treatment of Alzheimer's disease: cognitive and biological effects.
Biological psychiatry 1987;22(9):1067-78.
1987: Keefe R S; Mohs R C; Losonczy M F; Davidson M; Silverman J M; Kendler K S; Horvath T B; Nora R; Davis K L
Characteristics of very poor outcome schizophrenia.
The American journal of psychiatry 1987;144(7):889-95.
1987: Davidson M; Keefe R S; Mohs R C; Siever L J; Losonczy M F; Horvath T B; Davis K L
L-dopa challenge and relapse in schizophrenia.
The American journal of psychiatry 1987;144(7):934-8.
1987: Mohs R C; Breitner J C; Silverman J M; Davis K L
Alzheimer's disease. Morbid risk among first-degree relatives approximates 50% by 90 years of age.
Archives of general psychiatry 1987;44(5):405-8.
1987: Weiner M F; Davis B M; Mohs R C; Davis K L
Influence of age and relative weight on cortisol suppression in normal subjects.
The American journal of psychiatry 1987;144(5):646-9.
1987: Davidson M; Giordani A B; Mohs R C; Mykytyn V V; Platt S; Aryan Z S; Davis K L
Control of exogenous factors affecting plasma homovanillic acid concentration.
Psychiatry research 1987;20(4):307-12.
1987: Davis K L; Hollander E; Davidson M; Davis B M; Mohs R C; Horvath T B
Induction of depression with oxotremorine in patients with Alzheimer's disease.
The American journal of psychiatry 1987;144(4):468-71.
1987: Kanof P D; Coccaro E F; Johns C A; Siever L J; Davis K L
Platelet [3H]imipramine binding in psychiatric disorders.
Biological psychiatry 1987;22(3):278-86.
1987: Haroutunian V; Mantin R; Campbell G A; Tsuboyama G K; Davis K L
Cysteamine-induced depletion of central somatostatin-like immunoactivity: effects on behavior, learning, memory and brain neurochemistry.
Brain research 1987;403(2):234-42.
1987: Davidson M; Giordani A B; Mohs R C; Horvath T B; Davis B M; Powchik P; Davis K L
Short-term haloperidol administration acutely elevates human plasma homovanillic acid concentration.
Archives of general psychiatry 1987;44(2):189-90.
1987: Davidson M; Mohs R C; Hollander E; Zemishlany Z; Powchik P; Ryan T; Davis K L
Lecithin and piracetam in Alzheimer's disease.
Biological psychiatry 1987;22(1):112-4.
1987: Davidson M; Losonczy M F; Mohs R C; Powchick P; Freed L B; Kaminsky R; Davis K L
Effects of debrisoquin on plasma homovanillic acid concentration in schizophrenic patients.
Psychopharmacology bulletin 1987;23(3):407-10.
1987: Siever L J; Coccaro E F; Zemishlany Z; Silverman J; Klar H; Losonczy M F; Davidson M; Friedman R; Mohs R C; Davis K L
Psychobiology of personality disorders: pharmacologic implications.
Psychopharmacology bulletin 1987;23(3):333-6.
1986: Davis K L; Mohs R C
Cholinergic drugs in Alzheimer's disease.
The New England journal of medicine 1986;315(20):1286-7.
1986: Haroutunian V; Kanof P D; Tsuboyama G K; Campbell G A; Davis K L
Animal models of Alzheimer's disease: behavior, pharmacology, transplants.
The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 1986;13(4 Suppl):385-93.
1986: Haroutunian V; Kanof P D; Davis K L
Partial reversal of lesion-induced deficits in cortical cholinergic markers by nerve growth factor.
Brain research 1986;386(1-2):397-9.
1986: Silverman J M; Breitner J C; Mohs R C; Davis K L
Reliability of the family history method in genetic studies of Alzheimer's disease and related dementias.
The American journal of psychiatry 1986;143(10):1279-82.
1986: Kanof P D; Johns C; Davidson M; Siever L J; Coccaro E F; Davis K L
Prostaglandin receptor sensitivity in psychiatric disorders.
Archives of general psychiatry 1986;43(10):987-93.
1986: Hollander E; Mohs R C; Davis K L
Antemortem markers of Alzheimer's disease.
Neurobiology of aging 1986;7(5):367-407.
1986: Losonczy M F; Song I S; Mohs R C; Mathé A A; Davidson M; Davis B M; Davis K L
Correlates of lateral ventricular size in chronic schizophrenia, II: biological measures.
The American journal of psychiatry 1986;143(9):1113-8.
1986: Losonczy M F; Song I S; Mohs R C; Small N A; Davidson M; Johns C A; Davis K L
Correlates of lateral ventricular size in chronic schizophrenia, I: Behavioral and treatment response measures.
The American journal of psychiatry 1986;143(8):976-81.
1986: Greenwald B S; Mathé A A; Mohs R C; Levy M I; Johns C A; Davis K L
Cortisol and Alzheimer's disease, II: Dexamethasone suppression, dementia severity, and affective symptoms.
The American journal of psychiatry 1986;143(4):442-6.
1986: Davis K L; Davis B M; Greenwald B S; Mohs R C; Mathé A A; Johns C A; Horvath T B
Cortisol and Alzheimer's disease, I: Basal studies.
The American journal of psychiatry 1986;143(3):300-5.
1986: Hollander E; Mohs R C; Davis K L
Cholinergic approaches to the treatment of Alzheimer's disease.
British medical bulletin 1986;42(1):97-100.
1986: Davidson M; Kendler K S; Mohs R C; Hollander E; Ryan T; Davis K L
Effect of apomorphine infusion on plasma homovanillic acid in normal subjects.
Journal of psychiatric research 1986;20(2):131-5.
1986: Davidson M; Mohs R C; Hollander E; Davis B M; Ryan T; Horvath T B; Davis K L
Physostigmine in patients with Alzheimer's disease.
Psychopharmacology bulletin 1986;22(1):101-5.
1985: Kendler K S; Masterson C C; Davis K L
Psychiatric illness in first-degree relatives of patients with paranoid psychosis, schizophrenia and medical illness.
The British journal of psychiatry : the journal of mental science 1985;147():524-31.
1985: Mohs R C; Davis B M; Greenwald B S; Mathé A A; Johns C A; Horvath T B; Davis K L
Clinical studies of the cholinergic deficit in Alzheimer's disease. II. Psychopharmacologic studies.
Journal of the American Geriatrics Society 1985;33(11):749-57.
1985: Davis B M; Mohs R C; Greenwald B S; Mathé A A; Johns C A; Horvath T B; Davis K L
Clinical studies of the cholinergic deficit in Alzheimer's disease. I. Neurochemical and neuroendocrine studies.
Journal of the American Geriatrics Society 1985;33(11):741-8.
1985: Davidson M; Kendler K S; Davis B M; Horvath T B; Mohs R C; Davis K L
Apomorphine has no effect on plasma homovanillic acid in schizophrenic patients.
Psychiatry research 1985;16(2):95-9.
1985: Haroutunian V; Kanof P; Davis K L
Pharmacological alleviation of cholinergic lesion induced memory deficits in rats.
Life sciences 1985;37(10):945-52.
1985: Siever L J; Davis K L
Overview: toward a dysregulation hypothesis of depression.
The American journal of psychiatry 1985;142(9):1017-31.
1985: Mohs R C; Davis K L
Interaction of choline and scopolamine in human memory.
Life sciences 1985;37(2):193-7.
1985: Kanof P D; Greenwald B S; Mohs R C; Davis K L
Red blood cell choline. II: Kinetics in Alzheimer's disease.
Biological psychiatry 1985;20(4):375-83.
1985: Greenwald B S; Edasery J; Mohs R C; Shah N; Trigos G G; Davis K L
Red blood cell choline. I: Choline in Alzheimer's disease.
Biological psychiatry 1985;20(4):367-74.
1985: Deutsch S I; Halperin R; Stanley M; Davis K L
Effect of chronic haloperidol and quinacrine coadministration on striatal HVA levels and stereotypic behaviors in response to apomorphine in the rat.
Neurochemical research 1985;10(4):491-8.
1985: Davis B M; Davis K L; Mohs R C; Mathé A A; Rothpearl A B; Johns C A; Levy M I; Horvath T B
Evaluating prolactin response to dopamine agonists in schizophrenia. Methodological problems.
Archives of general psychiatry 1985;42(3):259-64.
1985: Davis K L; Davidson M; Mohs R C; Kendler K S; Davis B M; Johns C A; DeNigris Y; Horvath T B
Plasma homovanillic acid concentration and the severity of schizophrenic illness.
Science (New York, N.Y.) 1985;227(4694):1601-2.
1985: Schleifer S J; Keller S E; Siris S G; Davis K L; Stein M
Depression and immunity. Lymphocyte function in ambulatory depressed patients, hospitalized schizophrenic patients, and patients hospitalized for herniorrhaphy.
Archives of general psychiatry 1985;42(2):129-33.
1985: Mohs R C; Davis B M; Johns C A; Mathé A A; Greenwald B S; Horvath T B; Davis K L
Oral physostigmine treatment of patients with Alzheimer's disease.
The American journal of psychiatry 1985;142(1):28-33.
1985: Haroutunian V; Barnes E; Davis K L
Cholinergic modulation of memory in rats.
Psychopharmacology 1985;87(3):266-71.
1984: Rosen W G; Mohs R C; Johns C A; Small N S; Kendler K S; Horvath T B; Davis K L
Positive and negative symptoms in schizophrenia.
Psychiatry research 1984;13(4):277-84.
1984: Rosen W G; Mohs R C; Davis K L
A new rating scale for Alzheimer's disease.
The American journal of psychiatry 1984;141(11):1356-64.
1984: Kendler K S; Davis K L
Acute and chronic effects of neuroleptic drugs on plasma and brain homovanillic acid in the rat.
Psychiatry research 1984;13(1):51-8.
1984: Davis K L; Davis B M; Mathé A A; Mohs R C; Rothpearl A B; Levy M I; Gorman L K; Berger P
Age and the dexamethasone suppression test in depression.
The American journal of psychiatry 1984;141(7):872-4.
1984: Deutsch S I; Oldendorf W H; Davis K L
Brain uptake indices of guanidine and 4-aminopyridine.
Life sciences 1984;34(23):2279-80.
1984: Schleifer S J; Keller S E; Meyerson A T; Raskin M J; Davis K L; Stein M
Lymphocyte function in major depressive disorder.
Archives of general psychiatry 1984;41(5):484-6.
1984: Levy M I; Davis B M; Mohs R C; Kendler K S; Mathé A A; Trigos G; Horvath T B; Davis K L
Apomorphine and schizophrenia. Treatment, CSF, and neuroendocrine responses.
Archives of general psychiatry 1984;41(5):520-4.
1984: Losonczy M F; Mohs R C; Davis K L
Seasonal variations of human lumbar CSF neurotransmitter metabolite concentrations.
Psychiatry research 1984;12(1):79-87.
1984: Kendler K S; Masterson C C; Ungaro R; Davis K L
A family history study of schizophrenia-related personality disorders.
The American journal of psychiatry 1984;141(3):424-7.
1984: Small N E; Mohs R C; Halperin R; Rosen W G; Masterson C; Kendler K S; Horvath T B; Davis K L
A study of the reliability of reported premorbid adjustment in schizophrenic patients.
Biological psychiatry 1984;19(2):203-11.
1984: Kendler K S; Davis K L
Genetic control of apomorphine-induced climbing behavior in two inbred mouse strains.
Brain research 1984;293(2):343-51.
1984: Johns C A; Levy M I; Davis B M; Mohs R C; Kendler K S; Mathe A A; Trigos G; Horvath T B; Davis K L
Apomorphine and schizophrenia.
Psychopharmacology bulletin 1984;20(1):103-7.
1984: Siever L J; Davis K L
Dysregulation of the noradrenergic system in depression.
Psychopharmacology bulletin 1984;20(3):500-4.
1983: Deutsch S I; Mohs R C; Levy M I; Rothpearl A B; Stockton D; Horvath T; Coco A; Davis K L
Acetylcholinesterase activity in CSF in schizophrenia, depression, Alzheimer's disease and normals.
Biological psychiatry 1983;18(12):1363-73.
1983: Halperin R; Guerin J J; Davis K L
Chronic administration of three neuroleptics: effects of behavioral supersensitivity mediated by two different brain regions in the rat.
Life sciences 1983;33(6):585-92.
1983: Levy M I; Kendler K S; Mathé A A; Mohs R C; Denigris Y; Trigos G G; Axiotis A; Rothpearl A; Davis K L
Antipsychotic efficacy of fluotracen: a clinical trial.
Journal of clinical psychopharmacology 1983;3(3):189-92.
1983: Levy M I; Davis B M; Mohs R C; Trigos G C; Mathé A A; Davis K L
Gamma-hydroxybutyrate in the treatment of schizophrenia.
Psychiatry research 1983;9(1):1-8.
1983: Deutsch S I; Davis K L
Schizophrenia: a review of diagnostic and biological issues. II. Biological issues.
Hospital & community psychiatry 1983;34(5):423-37.
1983: Greenwald B S; Mohs R C; Davis K L
Neurotransmitter deficits in Alzheimer's disease: criteria for significance.
Journal of the American Geriatrics Society 1983;31(5):310-6.
1983: Deutsch S I; Davis K L
Schizophrenia: a review of diagnostic and biological issues. I. Diagnosis and prognosis.
Hospital & community psychiatry 1983;34(4):313-22.
1983: Kendler K S; Mohs R C; Davis K L
The effects of diet and physical activity on plasma homovanillic acid in normal human subjects.
Psychiatry research 1983;8(3):215-23.
1983: Pepper G M; Davis K L; Davis B M; Krieger D T
DST in depression is unaffected by altering the clock time of its administration.
Psychiatry research 1983;8(2):105-9.
1983: Hsieh J Y; Yang R K; Davis K L
Improved sample preparation before liquid-chromatographic determination of probenecid in cerebrospinal fluid.
Clinical chemistry 1983;29(1):213-4.
1983: Davis B M; Mathé A A; Mohs R C; Levy M I; Davis K L
Effects of propantheline bromide on basal growth hormone, cortisol and prolactin levels.
Psychoneuroendocrinology 1983;8(1):103-7.
1983: Davis K L; Mohs R C; Davis B M; Horvath T B; Greenwald B S; Rosen W G; Levy M I; Johns C A
Oral physostigmine in Alzheimer's disease.
Psychopharmacology bulletin 1983;19(3):451-3.
1983: Mohs R C; Rosen W G; Davis K L
The Alzheimer's disease assessment scale: an instrument for assessing treatment efficacy.
Psychopharmacology bulletin 1983;19(3):448-50.
1983: Johns C A; Greenwald B S; Mohs R C; Davis K L
The cholinergic treatment strategy in aging and senile dementia.
Psychopharmacology bulletin 1983;19(2):185-97.
1983: Greenwald B S; Davis K L
Experimental pharmacology of Alzheimer disease.
Advances in neurology 1983;38():87-102.
1982: Davis K L; Mohs R C
Enhancement of memory processes in Alzheimer's disease with multiple-dose intravenous physostigmine.
The American journal of psychiatry 1982;139(11):1421-4.
1982: Davis K L; Hsieh J Y; Levy M I; Horvath T B; Davis B M; Mohs R C
Cerebrospinal fluid acetylcholine, choline, and senile dementia of the Alzheimer's type.
Psychopharmacology bulletin 1982;18(4):193-5.
1982: Kendler K S; Hsieh J Y; Davis K L
Studies of plasma homovanillic acid as an index of brain dopamine function.
Psychopharmacology bulletin 1982;18(4):152-5.
1982: Rosenberg G S; Davis K L
The use of cholinergic precursors in neuropsychiatric diseases.
The American journal of clinical nutrition 1982;36(4):709-20.
1982: Stahl S M; Davis K L; Berger P A
The neuropharmacology of tardive dyskinesia, spontaneous dyskinesia, and other dystonias.
Journal of clinical psychopharmacology 1982;2(5):321-8.
1982: Mohs R C; Davis B M; Rosenberg G S; Davis K L; Krieger D T
Naloxone does not affect pain sensitivity, mood or cognition in patients with high levels of beta-endorphin in plasma.
Life sciences 1982;30(21):1827-33.
1982: Levy M I; DeNigris Y; Davis K L
Rapid antidepressant activity of melanocyte-inhibiting factor: a clinical trial.
Biological psychiatry 1982;17(2):259-63.
1982: Deutsch S I; Mohs R C; Davis K L
A rationale for studying the transmissibility of Alzheimer's disease.
Neurobiology of aging 1982;3(2):145-7.
1982: Levy M I; Mohs R C; Rosen W G; Davis K L
Research subject recruitment for gerontological studies of pharmacological agents.
Neurobiology of aging 1982;3(1):77-9.
1982: Rosenberg G S; Davis K L
Precursors of acetylcholine: considerations underlying their use in Tourette syndrome.
Advances in neurology 1982;35():407-12.
1982: Mohs R C; Davis K L
A signal detectability analysis of the effect of physostigmine on memory in patients with Alzheimer's disease.
Neurobiology of aging 1982;3(2):105-10.
1982: Davis B M; Brown G M; Miller M; Friesen H G; Kastin A J; Davis K L
Effects of cholinergic stimulation on pituitary hormone release.
Psychoneuroendocrinology 1982;7(4):347-54.
1981: Rothpearl A B; Mohs R C; Davis K L
Statistical power in biological psychiatry.
Psychiatry research 1981;5(3):257-66.
1981: Davis K L; Hollister L E; Mathé A A; Davis B M; Rothpearl A B; Faull K F; Hsieh J Y; Barchas J D; Berger P A
Neuroendocrine and neurochemical measurements in depression.
The American journal of psychiatry 1981;138(12):1555-62.
1981: Mohs R C; Davis K L; Levy M I
Partial reversal of anticholinergic amnesia by choline chloride.
Life sciences 1981;29(13):1317-23.
1981: Davis K L; Samuel A; Mathé A A; Mohs R C
Intracerebral des-tyrosine-gamma-endorphin inhibits methylphenidate induced locomotor activity.
Life sciences 1981;28(21):2421-4.
1981: Davis K L; Rosenberg G S
Induction of behavioral supersensitivity to apomorphine by DFP treatment.
Life sciences 1981;28(17):1953-9.
1981: Davis B M; Pfefferbaum A; Krutzik S; Davis K L
Lithium's effect of parathyroid hormone.
The American journal of psychiatry 1981;138(4):489-92.
1981: Kendler K S; Davis K L
The genetics and biochemistry of paranoid schizophrenia and other paranoid psychoses.
Schizophrenia bulletin 1981;7(4):689-709.
1981: Davis K L; Faull K F; Hollister L E; Barchas J D; Berger P A
Alterations in cerebrospinal fluid dopamine metabolites following physostigmine infusion.
Psychopharmacology 1981;72(2):155-60.
1980: Davis K L; Mohs R C; Davis B M; Horvath T B; Tinklenberg J R; Rosenberg G S; Levy M I
Human memory and the effects of physostigmine and choline chloride [proceedings]
Psychopharmacology bulletin 1980;16(4):27-8.
1980: Hollister L E; Davis K L; Berger P A
Subtypes of depression based on excretion of MHPG and response to nortriptyline.
Archives of general psychiatry 1980;37(10):1107-10.
1980: Berger P A; Watson S J; Akil H; Elliott G R; Rubin R T; Pfefferbaum A; Davis K L; Barchas J D; Li C H
beta-Endorphin and schizophrenia.
Archives of general psychiatry 1980;37(6):635-40.
1980: Mohs R C; Davis K L
Choline chloride effects on memory: correlation with the effects of physostigmine.
Psychiatry research 1980;2(2):149-56.
1980: Davis B M; Davis K L
CKholinergic mechanisms and anterior pituitary hormone secretion.
Biological psychiatry 1980;15(2):303-10.
1980: Hollister L E; Pfefferbaum A; Davis K L
Monitoring nortriptyline plasma concentrations.
The American journal of psychiatry 1980;137(4):485-6.
1980: Berger P A; Faull K F; Kilkowski J; Anderson P J; Kraemer H; Davis K L; Barchas J D
CSF monoamine metabolites in depression and schizophrenia.
The American journal of psychiatry 1980;137(2):174-80.
1980: Davis K L; Mohs R C; Tinklenberg J R; Hollister L E; Pfefferbaum A; Kopell B S
Cholinomimetics and memory. The effect of choline chloride.
Archives of neurology 1980;37(1):49-52.
1980: Mohs R C; Davis K L; Tinklenberg J R; Hollister L E
Choline chloride effects on memory in the elderly.
Neurobiology of aging 1980;1(1):21-5.
1980: Hollister L E; Davis K L; Berger P A
Apomorphine in schizophrenia.
Communications in psychopharmacology 1980;4(4):277-81.
1979: Davis K L; Hollister L E; Berger P A
Choline chloride in schizophrenia.
The American journal of psychiatry 1979;136(12):1581-4.
1979: Mohs R C; Davis K L; Tinklenberg J R; Hollister L E; Yesavage J A; Kopell B S
Choline chloride treatment of memory deficits in the elderly.
The American journal of psychiatry 1979;136(10):1275-7.
1979: Davis K L; Mohs R C; Tinklenberg J R
Enhancement of memory by physostigmine.
The New England journal of medicine 1979;301(17):946.
1979: Davis K L
Cholinomimetic treatment of neuropsychiatric disorders: a review of recent developments.
The Mount Sinai journal of medicine, New York 1979;46(5):455-9.
1979: Davis K L; Rosenberg G S
Is there a limbic system equivalent of tardive dyskinesia?
Biological psychiatry 1979;14(4):699-703.
1979: Davis K L; Hollister L E; Livesey J; Berger P A
Cerebrospinal fluid acetylcholinesterase in neuropsychiatric disorders.
Psychopharmacology 1979;63(2):155-9.
1979: Davis K L; Hollister L E; Vento A L; Beilstein B A; Rosekind G R
Dimethylaminoethanol (deanol): effect on apomorphine-induced stereotypy and an animal model of tardive dyskinesia.
Psychopharmacology 1979;63(2):143-6.
1979: Pfefferbaum A; Davis K L; Coulter C L; Mohs R C; Tinklenberg J R; Kopell B S
EEG effects of physostigmine and choline chloride in humans.
Psychopharmacology 1979;62(3):225-33.
1978: Hollister L E; Davis K L; Overall J E; Anderson T
Excretion of MHPG in normal subjects: implications for biological classification of affective disorders.
Archives of general psychiatry 1978;35(12):1410-5.
1978: Davis K L; Hollister L E; Fritz W C
Induction of dopaminergic mesolimbic receptor supersensitivity by haloperidol.
Life sciences 1978;23(15):1543-8.
1978: Davis K L; Yamamura H I
Cholinergic underactivity in human memory disorders.
Life sciences 1978;23(17-18):1729-33.
1978: Davis K L; Hollister L E; Berger P A; Vento A L
Studies on choline chloride in neuropsychiatric disease: human and animal data.
Psychopharmacology bulletin 1978;14(4):56-8.
1978: Hollister L E; Jenden D J; Amaral J R; Barchas J D; Davis K L; Berger P A
Plasma concentrations of choline in man following choline chloride.
Life sciences 1978;23(1):17-22.
1978: Davis K L; Mohs R C; Tinklenberg J R; Pfefferbaum A; Hollister L E; Kopell B S
Physostigmine: improvement of long-term memory processes in normal humans.
Science (New York, N.Y.) 1978;201(4352):272-4.
1978: Davis K L; Hollister L E; Vento A L; Simonton S
Choline chloride in methylphenidate- and apomorphine-induced stereotypy.
Life sciences 1978;22(24):2171-7.
1978: Davis K L; Berger P A; Hollister L E; Barchas J D
Cholinergic involvement in mental disorders.
Life sciences 1978;22(21):1865-71.
1978: Davis K L; Hollister L E; Vento A L; Simonton S
Choline chloride in animal models of tardive dyskinesia.
Life sciences 1978;22(19):1699-707.
1978: Davis K L; Berger P A
Pharmacological investigations of the cholinergic imbalance hypotheses of movement disorders and psychosis.
Biological psychiatry 1978;13(1):23-49.
1978: Davis K L; Hollister L E; Tepper J
Cholinergic inhibition of methylphenidate-induced stereotypy: oxotremorine.
Psychopharmacology 1978;56(1):1-4.
1978: Davis K L; Berger P A; Hollister L E; Defraites E
Physostigmine in mania.
Archives of general psychiatry 1978;35(1):119-22.
1977: Wermuth B M; Davis K L; Hollister L E; Stunkard A J
Phenytoin treatment of the binge-eating syndrome.
The American journal of psychiatry 1977;134(11):1249-53.
1977: Davis K L; Hollister L E; Goodwin F K; Gordon E K
Neurotransmitter metabolites in the cerebrospinal fluid of man following physostigmine.
Life sciences 1977;21(7):933-6.
1977: Davis K L; Berger P A; Hollister L E
Deanol in tardive dyskinesia.
The American journal of psychiatry 1977;134(7):807.
1977: Davis K L; Berger P A; Hollister L E; Simonton S C
Choline chloride in the treatment of Huntington's disease and tardive dyskinesia: a preliminary report.
Psychopharmacology bulletin 1977;13(3):37-8.
1977: De Fraites E G; Davis K L; Berger P A
Coexisting tardive dyskinesia and parkinsonism: a case report.
Biological psychiatry 1977;12(2):267-72.
1976: Davis K L; Hollister L E; Overall J; Johnson A; Train K
Physostigmine: effects on cognition and affect in normal subjects.
Psychopharmacology 1976;51(1):23-7.
1976: Hollister L E; Davis K L; Berger P A
Pituitary response to thyrotropin-releasing hormone in depression.
Archives of general psychiatry 1976;33(11):1393-96.
1976: Davis K L; Hollister L E; Barchas J D; Berger P A
Choline in tardive dyskinesia and Huntington's disease.
Life sciences 1976;19(10):1507-15.
1976: Davis K L; Hollister L E; Berger P A
Letter: Bacloffen in schizophrenia.
Lancet 1976;1(7971):1245.
1976: Davis K L; Berger P A; Hollister L E
Tardive dyskinesia and depressive illness.
Psychopharmacology communications 1976;2(2):125-30.
1975: Davis K L; Hossister L E; Berger P A
Thyrotropin-releasing hormone in schizophrenia.
The American journal of psychiatry 1975;132(9):951-3.
1975: Davis K L; Berger P A; Hollister L E
Letter: Choline for tardive dyskinesia.
The New England journal of medicine 1975;293(3):152.
1975: Hollister L E; Davis K L; Berger P A
Butaclamol hydrochloride in newly admitted schizophrenics.
Psychopharmacology communications 1975;1(5):493-500.
1975: Davis K L; Hollister L E; Berger P A; Barchas J D
Cholinergic imbalance hypotheses of psychoses and movement disorders: strategies for evaluation.
Psychopharmacology communications 1975;1(5):533-43.
1974: Davis K L; Qualls B; Hollister L; Stunkard A J
Letter: EEGs of "binge" eaters.
The American journal of psychiatry 1974;131(12):1409.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Kenneth Davis

Research Profile (preview)

Disorders

Activities & Behaviors

Concepts & Ideas

Anatomy

Chemicals & Drugs

Living Beings

Procedures

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Kenneth Davis (preview)

All Publications